Mapping cancer DNA to match patients with targeted drugs

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses. 2. Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible. 3. Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis. 4. ECOG PS 0 or 1. 5. Age \>/= 18 years. 6. Estimated life expectancy \>/= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months. 7. Measurable disease with RECIST v1.1 (or updated version). 8. Adequate organ function. 9. Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents. 10. Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form). 11. Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials. Exclusion criteria: 1. Unable or unwilling to consent to the above tissue and blood requirements. 2. Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy. 3. Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators. 4. Unwilling to receive medically actionable findings (germline and/or somatic).